H3 HARMONY BIOSCIENCES

Harmony Biosciences Announces Date of First Quarter 2021 Financial Results

April 27, 2021

PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare, neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's first quarter 2021 financial results on Tuesday, May 11, 2021 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.

To participate in the call, please dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 2269379. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

A replay of the call will be available within 24 hours by dialing (855) 859-2056 (domestic) or +1 (404) 537-3406 (international) and entering conference ID: 2269379. The replay will be available until May 18, 2021.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare, neurological disorders who have unmet medical needs. For more information on Harmony Biosciences, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Investor Contact: Lisa Caperelli 610-608-0215 Icaperelli@harmonybiosciences.com

Harmony Biosciences Media Contact: Nancy Leone 215-891-6046 nleone@harmonybiosciences.com